Crinetics Pharmaceuticals CRNX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Neurocrine BiosciencesNBIX

——

Corcept TherapeuticsCORT

——

Rhythm Pharmaceuticals, Inc.RYTM

——

BridgeBio PharmaBBIO

——

Lantheus HoldingsLNTH

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's remainder of fiscal year 2024?: Crinetics Pharmaceuticals (CRNX) reported remainder of fiscal year 2024 of $5.1M in Q1 2026.